Statistics for Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro

Total visits

views
Immunogenicity and safety following a homologous booster dose of a SARSCoV2 recombinant spike protein vaccine with MatrixMTM adjuvant NVXCoV2373 versus a primary series in people living with and without HIV1 infection in South Africa A randomized cro 1

Total visits per month

views
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 1
May 2025 0

File Visits

views
Journal Article.pdf 5